Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A SparanoRobert J GrayPeter M RavdinDella F MakowerKathleen I PritchardKathy S AlbainDaniel F HayesCharles E GeyerElizabeth C DeesMatthew P GoetzJohn A OlsonTracy LivelySunil S BadveThomas J SaphnerLynne I WagnerTimothy J WhelanMatthew J EllisSoonmyung PaikWilliam C WoodMaccon M KeaneHenry L Gomez MorenoPavan S ReddyTimothy F GogginsIngrid A MayerAdam M BrufskyDeborah L ToppmeyerVirginia G KaklamaniJeffrey L BerenbergJeffrey AbramsGeorge W SledgePublished in: The New England journal of medicine (2019)
Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).